Clinuvel Pharmaceuticals Ltd (CUV) — Cash Flow Quality Index
Clinuvel Pharmaceuticals Ltd (CUV) has a Cash Flow Quality Index of 1.20x as of December 2025. Operating cash flow of AU$12.52 Million exceeds net income of AU$10.44 Million, indicating high earnings quality where cash backs reported profits. Explore CUV debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Clinuvel Pharmaceuticals Ltd Cash Flow Quality Index (2017–2025)
Historical Cash Flow Quality Index for Clinuvel Pharmaceuticals Ltd across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see how efficiently does Clinuvel Pharmaceuticals Ltd generate cash.
Annual Cash Flow Quality Index for Clinuvel Pharmaceuticals Ltd (2017–2025)
Year-by-year earnings quality comparison for Clinuvel Pharmaceuticals Ltd.
| Year | Quality Index | Operating CF (AUD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.14x | AU$41.10 Million | AU$36.17 Million | ▲ +9.3% |
| 2024 | 1.04x | AU$37.05 Million | AU$35.64 Million | ▼ -13.8% |
| 2023 | 1.21x | AU$36.91 Million | AU$30.60 Million | ▼ -36.8% |
| 2022 | 1.91x | AU$39.87 Million | AU$20.88 Million | ▲ +145.2% |
| 2021 | 0.78x | AU$19.26 Million | AU$24.73 Million | ▼ -17.4% |
| 2020 | 0.94x | AU$14.19 Million | AU$15.05 Million | ▼ -7.4% |
| 2019 | 1.02x | AU$18.46 Million | AU$18.13 Million | ▲ +15.1% |
| 2018 | 0.88x | AU$11.69 Million | AU$13.22 Million | ▼ -36.0% |
| 2017 | 1.38x | AU$9.92 Million | AU$7.18 Million | — |